• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Distinct blood inflammatory biomarker clusters stratify host phenotypes during the middle phase of COVID-19

tetano

Editor, Senior Moderator
Sci Rep


. 2022 Dec 28;12(1):22471.
doi: 10.1038/s41598-022-26965-7.
Distinct blood inflammatory biomarker clusters stratify host phenotypes during the middle phase of COVID-19


Paul W Blair[SUP] 1 2 [/SUP], Joost Brandsma[SUP] 3 [/SUP], Josh Chenoweth[SUP] 3 [/SUP], Stephanie A Richard[SUP] 3 4 [/SUP], Nusrat J Epsi[SUP] 3 4 [/SUP], Rittal Mehta[SUP] 3 [/SUP], Deborah Striegel[SUP] 3 [/SUP], Emily G Clemens[SUP] 5 [/SUP], Sultanah Alharthi[SUP] 3 5 [/SUP], David A Lindholm[SUP] 6 7 [/SUP], Ryan C Maves[SUP] 8 9 [/SUP], Derek T Larson[SUP] 10 [/SUP], Katrin Mende[SUP] 3 4 7 [/SUP], Rhonda E Colombo[SUP] 3 4 11 [/SUP], Anuradha Ganesan[SUP] 3 4 12 [/SUP], Tahaniyat Lalani[SUP] 3 4 13 [/SUP], Christopher J Colombo[SUP] 11 [/SUP], Allison A Malloy[SUP] 14 [/SUP], Andrew L Snow[SUP] 15 [/SUP], Kevin L Schully[SUP] 16 [/SUP], Charlotte Lanteri[SUP] 4 [/SUP], Mark P Simons[SUP] 4 [/SUP], John S Dumler[SUP] 5 [/SUP], David Tribble[SUP] 4 [/SUP], Timothy Burgess[SUP] 4 [/SUP], Simon Pollett[SUP] 3 4 [/SUP], Brian K Agan[SUP] 3 4 [/SUP], Danielle V Clark[SUP] 3 [/SUP]; EPICC COVID-19 Cohort Study Group



Collaborators, Affiliations

Abstract

The associations between clinical phenotypes of coronavirus disease 2019 (COVID-19) and the host inflammatory response during the transition from peak illness to convalescence are not yet well understood. Blood plasma samples were collected from 129 adult SARS-CoV-2 positive inpatient and outpatient participants between April 2020 and January 2021, in a multi-center prospective cohort study at 8 military hospitals across the United States. Plasma inflammatory protein biomarkers were measured in samples from 15 to 28 days post symptom onset. Topological Data Analysis (TDA) was used to identify patterns of inflammation, and associations with peak severity (outpatient, hospitalized, ICU admission or death), Charlson Comorbidity Index (CCI), and body mass index (BMI) were evaluated using logistic regression. The study population (n = 129, 33.3% female, median 41.3 years of age) included 77 outpatient, 31 inpatient, 16 ICU-level, and 5 fatal cases. Three distinct inflammatory biomarker clusters were identified and were associated with significant differences in peak disease severity (p < 0.001), age (p < 0.001), BMI (p < 0.001), and CCI (p = 0.001). Host-biomarker profiles stratified a heterogeneous population of COVID-19 patients during the transition from peak illness to convalescence, and these distinct inflammatory patterns were associated with comorbid disease and severe illness due to COVID-19.
 
Back
Top Bottom